CGS-authored
Early in 2004, the high-profile biotech company Geron predicted that clinical trials of its first stem cell therapy would start within a year.
Like clockwork, they've made the same promise at least eight times since.
February 22, 2004: "The company believes it will be cleared to start the first stem-cell therapy in human tests next year, possibly for spinal-cord injury."
December 1, 2004: "According to Geron CEO Thomas Okarma [right], the company is aiming to file an investigational new drug application with the U.S. Food and Drug Administration (FDA) requesting permission to begin clinical trials using glial cells derived from embryonic stem cells to repair damaged spinal cords in 2005 or early 2006."
February 25, 2005: "Next year [Hans Keirstead] and his corporate partner, Geron, plan to try treating people who have recent spinal cord injuries, in what would almost certainly be the first human trial of any therapy derived from such cells.
April 19, 2005: Okarma "said he believes the clinical trial could begin in mid-2006."
September 9, 2005: "Geron plans to begin clinical trials on acute...